Brief Report: Impact of Maintenance Pemetrexed Cessation on Clinical Outcomes of Patients With Metastatic Nonsquamous NSCLC

Introduction: Combination chemoimmunotherapy including pemetrexed and a PD(L)1 inhibitor is a common first-line systemic therapy approach for patients with metastatic nonsquamous NSCLC. Patients often discontinue maintenance pemetrexed due to adverse effects, and little is known about the impact of...

Full description

Bibliographic Details

Published in:	JTO Clinical and Research Reports
Main Authors:	Shreya Bhatia, BS, Matthew Lu, MD, Spencer Lessans, MD, Michael Libre, BA, Heidi Chen, PhD, Wade T. Iams, MD
Format:	Article
Language:	English
Published:	Elsevier 2024-11-01
Subjects:	Non–small cell lung cancer Chemoimmunotherapy Pemetrexed Pembrolizumab
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666364324000870